27 October 2025
Novartis (NVS) agreed to buy biotechnology company Avidity in a deal valued at $12 billion, making it the Swiss drugmaker’s biggest acquisition in more than a decade and adding several potential blockbuster treatments as generic competition looms for its current top-sellers.
Sam Fazeli of Bloomberg Intelligence has more.
AI-Powered Stock Picking
Trade Idea of the Week: ROAD (Construction Partners)
Construction Partners is a BUY for Danelfin AI. We highlight every week a stock with a high win rate track record.
